These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Elevated blood glucose after compound 48/80 treatment is not related to hepatic mast cell degranulation in rats. Dimlich RV; Reilly FD Proc Soc Exp Biol Med; 1986 Dec; 183(3):321-7. PubMed ID: 3797416 [TBL] [Abstract][Full Text] [Related]
8. Lack of involvement of mast cell degranulation in the antiarrhythmic effect of preconditioning in rats. Humphreys RA; Kane KA; Parratt JR J Cardiovasc Pharmacol; 1998 Mar; 31(3):418-23. PubMed ID: 9514187 [TBL] [Abstract][Full Text] [Related]
9. Hepatic microvascular regulatory mechanisms. III. Aminergic mechanisms as related to mast cells. Reilly FD; Dimlich RV; Cilento EV; McCuskey RS Int J Microcirc Clin Exp; 1983; 2(1):61-73. PubMed ID: 6678839 [TBL] [Abstract][Full Text] [Related]
10. Improved survival from compound 48/80-induced lethal stress and inhibition of myocardial histamine and carnosine mobilization by lodoxamide. Flancbaum L; Fitzpatrick JC; Fisher H Circ Shock; 1989 Feb; 27(2):155-64. PubMed ID: 2706750 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of oxidative enzymes by anti-allergy drugs. White GJ Agents Actions; 1981 Nov; 11(5):503-9. PubMed ID: 6121476 [TBL] [Abstract][Full Text] [Related]
12. Effect of H1 and H2 receptor blockers on mobilization of myocardial carnosine to histamine during compound 48/80-induced shock in young rats. Fitzpatrick JC; Fisher H; Flancbaum L Circ Shock; 1990 Feb; 30(2):145-53. PubMed ID: 1968787 [TBL] [Abstract][Full Text] [Related]
14. The characterization of lodoxamide, a very active inhibitor of mediator release, in animal and human models of asthma. Johnson HG; Sheridan AQ Agents Actions; 1986 Jun; 18(3-4):301-5. PubMed ID: 2875630 [TBL] [Abstract][Full Text] [Related]
16. Allopurinol and lodoxamide in complement-induced hepatic ischemia. Schirmer WJ; Schirmer JM; Naff GB; Fry DE J Surg Res; 1988 Jul; 45(1):28-36. PubMed ID: 3260642 [TBL] [Abstract][Full Text] [Related]
17. Addition of a mast cell stabilizing compound to organ preservation solutions decreases lung reperfusion injury. Barr ML; Carey JN; Nishanian GP; Roberts RF; Sakamaki Y; Darbinian SH; Starnes VA J Thorac Cardiovasc Surg; 1998 Mar; 115(3):631-6; discussion 636-7. PubMed ID: 9535451 [TBL] [Abstract][Full Text] [Related]
18. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent. Levrier J; Duval D; Prouteau M; Voltz C; Berry CN; Lloyd KG; Scatton B Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995 [TBL] [Abstract][Full Text] [Related]
19. Effect of lodoxamide on the secretory response induced by Escherichia coli and Vibrio cholerae enterotoxins in infant mice. Knoop FC; Thomas DD Infect Immun; 1984 May; 44(2):406-8. PubMed ID: 6143729 [TBL] [Abstract][Full Text] [Related]
20. Lodoxamide tromethamine treatment for superior limbic keratoconjunctivitis. Grutzmacher RD; Foster RS; Feiler LS Am J Ophthalmol; 1995 Sep; 120(3):400-2. PubMed ID: 7661218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]